← Russell 3000 cross-section

BAX BAXTER INTERNATIONAL INC

Trailing twelve months to 2026-06-30 · as filed 2026-07-30, not restated
Healthcare

Scale

Market cap
$13.6bn
Revenue TTM
$11.5bn
Net income TTM
$-1.1bn
Free cash flow
Composite score
Sector rank
#577

Valuation

P / E
EV / EBITDA
16.9
EV / sales
1.0
FCF yield
Earnings yield vs 10-yr
-12.54pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-9.3%
EBITDA margin
5.9%
ROE
-17.1%
ROIC
-6.8%
Revenue growth
5.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Additionally, sales of products and services provided directly through certain of our manufacturing facilities related to Infusion Therapies & Platforms that were previously reported in Other are now reported in our Infusion Therapies & Platforms division of the Medical Products & Therapies segment. NON-GAAP FINANCIAL MEASURES Our presentation of percentage changes in net sales at organic sales growth excludes the impact of the Kidney Care Manufacturing and Supply Agreement (Kidney Care MSA) sales not reflected in reportable segments, impacts associated with business acquisitions or divestitures, and is calculated at constant currency rates. …BAXTER INTERNATIONAL INC, 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →